|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The quality of molec- ular response to chemotherapy is predictive for the outcome of AML1 - ETO - positive AML and is independent of pretreatment risk factors 显示文摘 | Weisser M Haferlach C Hiddemann W | 2007 | Leukemia2007，21，6： | 1 |
| 2 | Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincrlstine, and prednlsone (CHOP) significantly improves the outcome for patients with advanced - stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low - Grade Lymphoma Study Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 3 | Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse显示文摘 | Buchner T Hiddemann W Koenigsmann M | 1991 | Blood1991，78，5： | 1 |
| 4 | Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML cooperative group 显示文摘 | BUCHNER T HIDDEMANN W WORMANN B | 1999 | Blood1999，93，12： | 1 |
| 5 | Primary lymphoma of the stomach: Three-year results of a prospective multicenter study显示文摘 | P. Koch B. Grothaus-Pinke W. Hiddemann N. Willich B. Reers F. del Valle H. Bodenstein M. Pfreundschuh E. M?ller J. Kocik R. Parwaresch M. Tiemann | 1997 | Annals of Oncology1997，，0： | 1 |
| 6 | Current therapeutic strategies in the management of acute myeloid leukemia显示文摘 | FIEGL M HIDDEMANN W BRESS J | 2007 | Med Klin(Munich)2007，102，4： | 1 |
| 7 | Frontline therapywith rituximab added to the combination of cyclophosphamide,doxorubicin, vincristine, and prednisone(CHOP) significantly improves the outcome for patientswith advanced-stage follicular lymphoma compared withtherapy with CHOP alone: results of a prospective randomizedstudy of the German Low -Grade LymphomaStudy Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 8 | Gemcitabine as a singleagent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma显示文摘 | Fossa A Santoro A Hiddemann W | 1999 | J Clin Oncol1999，17，： | 1 |
| 9 | Rituximab is the essential treatment modality that underlies the significant improvement in short and long term outcome of patients with advanced stage follicular lymphoma-a 10 year analysis of GLSG trials显示文摘 | Hiddemann W Hoster E Buske C | 2006 | Blood2006，108，： | 1 |
| 10 | Gemcitabine as a single in the treatment of relapsed or refractory aggressive non-nodgkin's lymphoma 显示文摘 | Fossa A Santoro W Hiddemann L | 1999 | J Clin Oncol1999，17，12： | 1 |
| 11 | Improvement of hammerhead ribozymes cleaving mdr-1 Mrna显示文摘 | Kneba M Hiddemann W | 1995 | Biol Chem Hoppe Seyler1995，376，5： | 1 |
| 12 | Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive Non-Hodgkin's lymphoma显示文摘 | Santoro A Hiddemann W | 1999 | J Clin Oncol1999，17，12： | 1 |
| 13 | Elevated ex- pression of SLOOP, CAPL and MAGE 3 in doxorubicin-re- sistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and sub- tractive suppressive hybridization for the analysis of dif- ferential gene expression显示文摘 | Bertram J Palfner K Hiddemann W | 1998 | Anticancer Drugs1998，9，4： | 1 |
| 14 | Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor -alpha- induced apoptosis in MCF - 7 mad other epithelial tumor cells显示文摘 | Binder C Schulz M Hiddemann W Oellerich M | 1999 | Lab Invest1999，79，： | 1 |
| 15 | Gemcitabine as a singal agent in the treatment of relapsed or refractory aggressive non-Hodgkin's Lymphoma显示文摘 | Fossa A Santoro A Hiddemann W | 1999 | J Clin Oncol1999，17，12： | 1 |
| 16 | Frontline therapy with rituximab added to the combination of cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 17 | Promoter methylation and expression of DNA repair genes hM I,H1 and MGMT in acute myeloid leukemia显示文摘 | Lenz G Hutter G Hiddemann W | 2004 | Ann Hematol2004，83，10： | 1 |
| 18 | Doublt induction strategy for acutcmyeloid leukemia:the effect of high-dose cylarabine with mitoxantrone instead of standard dose cyturadine with daunorubicin and 6-thioguanine:arandomized trial by the German Aml Cooperative Gnup显示文摘 | Buchner T Hiddemann W Wormann B | 1999 | Blood1999，93，12： | 1 |
| 19 | Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma显示文摘 | Fossa A Santoro A Hiddemann W | 1997 | J Clin Oncol1997，17，12： | 1 |
| 20 | Increaseof P-glyco-protein-mediateddrugresista ncebyhsp 90 beta 显示文摘 | Bertram J Palfnerk Hiddemann Wetal | 1996 | Anticancer Drug1996，7，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员